Good Time to look at Optimer (OPTR $12.00) Pharmaceuticals
On Feb.11 Optimer completed a 6M share offering of common stock at a price of $11.25 sh. and the stock has held up well despite the dilution. On February 7 the Company announced a deal with Astellas Pharmaceutical licensing off rights to their Fidaxomycin C.diff drug for Europe, parts of...
Biotech Stocks Get A Boost from the BIO CEO Conference:Exelixis(EXEL)and Optimer(OPTR)
BIO CEO and Investor Conference Feb 14-15 Biotechnology stocks picked up some buying interest today from the BIO CEO Conference in NYC. CNBC provided some CEO clips from Exelixis (EXEL $10.58) up 7%, Onyxx(ONXX $36.28) up 0.28% and Optimer (OPTR $11.61) up 2.83%. Onyyx is a cancer drug...
Biotechnology Portfolio Notes:CEPH,IVD,SRLS
Techs (QLD up 1.23%) outperformed biotechs today as Cisco bad news was forgotten. Biotech stocks treaded water today as all major ETF's were flat. On the news front: Cephalon(CEPH $58.20) was down 3.17% on heavy volume as investors sold on there earnings report and an FDA subpoena about their...
Rayno LifeScience Portfolio: Sequenom(SQNM) News and AlbanyMR(AMRI) Added
Biotechnology Rally Underway The NASDAQ market recovered from near 1% losses today caused by the Cisco(CSCO) earnings report and guidance. The NASDAQ is currently flat to slightly down at 2785 recovering from the 2760 level. Expectations that Egypt's President Mubarak would resign helped the...
Investors want More from Earnings:Genomic Health (GHDX),Illumina(ILMN) Others
Life Sciences Market Remains Strong while M&A Provides Support As we enter the peak earnings season for many tools and device companies, initial reports would indicate that investor expectations are higher and stocks could have a bit of profit taking. Genomic Health(GHDX $22.11) Turns a...